-
- Nicole Véronique Smadja
- From the Research Cytogenetic Laboratory, Hôpital Saint-Antoine, Paris; Genetic Laboratory, INSERM EMI9906, IFRMP23, Centre Henri Becquerel, Rouen; Hematology Laboratory, Hôpital Universitaire Dupuytren, Limoges; Onco-Hematology Genetic Laboratory, Centre Hospitalier Universitaire, Grenoble; Hematology Department, Hôpital Jacques Monod, Le Havre, France.
-
- Christian Bastard
- From the Research Cytogenetic Laboratory, Hôpital Saint-Antoine, Paris; Genetic Laboratory, INSERM EMI9906, IFRMP23, Centre Henri Becquerel, Rouen; Hematology Laboratory, Hôpital Universitaire Dupuytren, Limoges; Onco-Hematology Genetic Laboratory, Centre Hospitalier Universitaire, Grenoble; Hematology Department, Hôpital Jacques Monod, Le Havre, France.
-
- Christophe Brigaudeau
- From the Research Cytogenetic Laboratory, Hôpital Saint-Antoine, Paris; Genetic Laboratory, INSERM EMI9906, IFRMP23, Centre Henri Becquerel, Rouen; Hematology Laboratory, Hôpital Universitaire Dupuytren, Limoges; Onco-Hematology Genetic Laboratory, Centre Hospitalier Universitaire, Grenoble; Hematology Department, Hôpital Jacques Monod, Le Havre, France.
-
- Dominique Leroux
- From the Research Cytogenetic Laboratory, Hôpital Saint-Antoine, Paris; Genetic Laboratory, INSERM EMI9906, IFRMP23, Centre Henri Becquerel, Rouen; Hematology Laboratory, Hôpital Universitaire Dupuytren, Limoges; Onco-Hematology Genetic Laboratory, Centre Hospitalier Universitaire, Grenoble; Hematology Department, Hôpital Jacques Monod, Le Havre, France.
-
- Christophe Fruchart
- From the Research Cytogenetic Laboratory, Hôpital Saint-Antoine, Paris; Genetic Laboratory, INSERM EMI9906, IFRMP23, Centre Henri Becquerel, Rouen; Hematology Laboratory, Hôpital Universitaire Dupuytren, Limoges; Onco-Hematology Genetic Laboratory, Centre Hospitalier Universitaire, Grenoble; Hematology Department, Hôpital Jacques Monod, Le Havre, France.
説明
<jats:p>Conventional karyotypes performed before any treatment in 208 patients with multiple myeloma were reviewed by the Groupe Français de Cytogénétique Hématologique. A total of 138 patients displayed complex chromosomal abnormalities (CCAs). According to the chromosome number pattern, a first group of 75 patients had a hyperdiploid karyotype. A second group of 63 patients referred to as the hypodiploid group had either pseudodiploid, hypodiploid, or near-tetraploid karyotypes. Of 159 treated patients available for survival analysis, 116 had an abnormal karyotype. The comparison of overall survival (OS) between hyperdiploid and hypodiploid patients showed a highly significant difference (median OS 33.8 vs 12.6 months, respectively, P < .001). The presence of 14q32 rearrangements (36 of 116 patients) worsened the prognosis (median OS 17.6 vs 29.9 months, P < .02). The presence of chromosome 13q abnormalities (13qA, 63 patients) did not modify OS in CCA patients (median OS 20.6 vs 27.8 months,P < .59). However, taking into account the whole series including normal karyotypes, 13qA (63 of 159 patients) had a significant impact on OS (median 20.6 vs 37.1 months,P < .04). In the same way, the presence of a hypodiploid karyotype (52 of 159 patients) had a strong prognostic value (OS 12.8 vs 44.5 months, P < .000 01). A multivariate analysis including stage, β2-microglobulin, bone marrow plasmocytosis, treatment type, 13qA, and hyperdiploidy and hypodiploidy showed that a hypodiploid karyotype was the first independent factor for OS (P < .001), followed by treatment approach. These results confirm that the chromosome number pattern of malignant plasma cells is a very powerful prognostic factor in newly diagnosed multiple myeloma patients.</jats:p>
収録刊行物
-
- Blood
-
Blood 98 (7), 2229-2238, 2001-10-01
American Society of Hematology
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1361137044106592896
-
- NII論文ID
- 30022493285
-
- ISSN
- 15280020
- 00064971
-
- データソース種別
-
- Crossref
- CiNii Articles